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ABSTRACT
The Jun activation domain-binding protein 1 (Jab1), aside from being an activator protein 1 coactivator, is involved in
degradation of the cyclin-dependent kinase inhibitor p27Kip1, a dosage-dependent tumor suppressor protein. The
antisense effect was confirmed in an oral tongue cancer cell line Supri’s clone-1 (Sp-C1). In this study, the antisense-
mediated apoptosis of Sp-C1 derived cultures was analized. Jab1-antisense (Jab1-AS) treatment induced apoptosis
characterized by an increase in the early apoptosis (33.5%) and late apoptosis (17.6%). Also, the proteolitic activation
of caspase-3 and caspase-9 was increased. These data suggest that Jab1 AS could induce apoptosis in oral tongue
cancer cell (Sp-C1). Targeting this molecule could represent a promising new therapeutic approach for this type of
cancer.
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ABSTRAK
Jun activation domain-binding protein (Jab1) berperan sebagai koaktivator dari aktivator protein 1 yang terlibat dalam
degradasi cyclin-dependent kinase inhibitor p27Kip1. Efek Jab1 antisense (Jab1-AS) diujikan pada sel kanker lidah
manusia Supri’s-Clone 1 (Sp-C1). Tujuan penelitian ini adalah menganalisis hambatan sel SP-C1 dengan perlakuan
Jab1-AS. Hasil penelitian menunjukkan bahwa Jab1-AS meningkatkan apoptosis yang ditandai dengan meningkatnya
fase awal apoptosis (33,5%) dan fase lambat apoptosis (17,6%). Selain data tersebut, diketahui peningkatan aktivitas
proteolitik caspase-3 dan caspase-9 pada sel yang diperlakukan dengan Jab1 AS. Kesimpulannya, Jab1 AS dapat
meningkatkan apoptosis sel kanker lidah manusia (Sp-C1). Target pada molekul Jab1 dapat memberikan harapan baru
sebagai pendekatan terapeutik untuk jenis kanker tersebut.
Kata kunci: Jab1, apoptosis, antisense, kanker lidah manusia (Sp-C1).
INTRODUCTION
Human oral tongue squamous cell carcinoma (OTSCC) accounts for the majority ofmalignancies that arise in head and neck region.1 OTSCC is characterized by a high degree
of local invasion and a high rate of metastases to the cervical lymph nodes. Moreover, human
oral tongue cancer cells frequenly shows local recurrence after initial treatment, probably due
to microinvasion and/or micrometastasis of the tumor cells at the primary site. Therefore, the
ratio of mortality/incidence in 1980 and 1990 was 0.48 and 0.47, respectively, and the
prognosis has not changed during the past 10 years.2,3
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The human Jab1 was originally identified as a
coactivator of the gene-regulatory AP-1 proteins (Jun/Fos
proto-oncogenes) involved in the control of cell
proliferation.4 Jab1 is also known as COP9 singnalosome
subunit 5 (CSN5), which is a component of the COP9
singnalosome regulatory complex.5,6 Recently, it was
demonstrated that Jab1 can specifically interact with the
cyclin-dependent kinase (CDK) inhibitor protein p27Kip1.7
Transient coexpression of Jab1 with p27Kip1 accelerated
the degradation of p27Kip1 in mammalian cells by
translating p27Kip1 from the nucleus to the cytosol, in
which degradation could occur.7 p27Kip1 is a universal
CDK inhibitor that directly inhibits the enzymatic activity
of cyclin-CDK complexes, resulting in cell cycle arrest at
G1.8 Recently, decreased expression of p27Kip1 has been
frequently detected in human cancer,9-15 including head
and neck carcinoma.16-20 These studies indicated that
p27Kip1 protein level may be associated with the develop-
ment of human cancers and appear as an important
marker of cancer progression. In the latter study, Jab1
overexpression was inversely associated with p27Kip1
levels .21-24 However, to the best of our knowledge, the
status of Jab1 expression in human oral tongue cancer
has not been examined.
In the present study, the mechanism of the observed
growth inhibition induced by Jab1 AS was explored.
Antisense oligonucleotides into human oral tongue
cancer cell lines (Sp-C1) that had exhibited amplification
and consequent overexpression of the gene was
transfected. 
MATERIALS AND METHODS
Cell and Cell Culture 
Oral tongue squamous cell carcinoma cell lines (Sp-
C1) was used in this study. Sp-C1 cell line was establised in
our laboratory.25-28 The cell line was grown in Dulbecco’s
modified Eagle medium (DMEM, Sigma, St Louis, MO,
USA) supplemented with 10% fetal calf serum (FCS,
Moregate BioTech, Bulimba, Australia), and 100 μg/ml
streptomycin, 100 units/ml penicillin (Invitrogen Corp.,
Carlsbad, CA, USA). Sp-C1 cell cultures were incubated in
humidified atmosphere of 95% air and 5% Co2 at 37oC.
Antisense Experiments
Antisense experiments were performed as described
previously.24 Briefly, two oligonucleotides containing
phosphorothioate backbones were synthesized (Fasmac ,
Japan) as follows: AS, 5’-CGGACGCCGCCATCGCCGA-
GGAAG-3’ (the antisense direction of human Jab1 cDNA
nucleotides 15 to 24), Sense (S), 5’-CCTCTTACCTC
AGTTACAATTTATA-3’ (the sense direction of human Jab1
cDNA nucleotides 15 to 25). The oligonucleotides were
transfected into Sp-C1 cells using Tris-EDTA reagent
according to the manufacturer’s instructions.
Flow Cytometry
Cells were seeded on 100 mm dish (Falcon, USA) at
2x105 cells/well in DMEM containing 10% FCS. After 72
hours, the sticked and floating cells were collected in
conical tube (Falcon, USA). Then, the cells were incubated
with 5μl FITC and propidium iodine (PI) in 500 μl binding
buffer (Annexin V-FITC, Bio Vision Inc, CA). Flow
cytometry was analysed by a digital flow cytometry
system EPICS (Coulter, Miami, FL, USA).
Caspase-3 and –9 Activity
Caspase-3 and -9 activity were measured using the
colorimetric assay kit (BioVision, caspase-3/CPP32 and
caspase-9/Mch6 colorimetric assay kit, CA, USA)
according to the manufacturer’s directions. This test is
based on the addition of a caspase-specific peptide
conjugated to a color reporter molecule p-nitroanilide.
The cleavage of the peptide by caspase releases the
chromophore p-NA, which is quantitated spectrophoto-
metrically at 405 nm.30 Briefly, equal amounts of cell
extracts prepared from Sp-C1 cells treated with AS or S
were incubated with the substrate (DVED-pNA and LEHD-
pNA) in the assay buffer for 2 hours at room temperature.
Absorbance was measured at 405 nm using a microplate
reader (Bio-Rad Laboratories, Hercules, CA). Each
determination was performed in triplicate.
Statistical Analysis
Statistical differences between the means for the
different groups were evaluated with Stat View 4.5
(version 5.0J, SAS Institute Inc, Cary, NC, USA) using one-
way ANOVA and t-test. The significance level was set at
5% for each analysis.
RESULTS
Flow Cytometry Analysis
To determine whether down regulation of Jab1 protein
can induce apoptosis, flow cytometry analysis was
performed on each transfectant. Flow cytometry analysis
demonstrated that high percentage of early apoptosis
was detected in Sp-C1 Jab1 AS (33.5%) compared with
that of Sp-C1 Jab1 S (18.8%). Furthermore, percentage of
late apoptosis was found in Sp-C1 Jab1 AS (17.6%)
compared with of Sp-C1 Jab1 S (17.6%) (Fig.1). 
Kip 1 Induces Apoptosis by Activation of Caspases
The activity of caspase-3 and -9 in Sp-C1 cancer cells
treated with or without oligonucleotide (AS and S) for 72
h was examined. As seen in Fig. 2, Sp-C1 Jab1 AS showed
increased caspase-3 (2.4 fold) and -9 (1.9 fold) proteolytic
activity compared with the respective neo-transfectant or
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sense treated cell. These data suggest that Sp-C1 Jab1 AS
induced apoptosis through external and internal pathways.
Discussion
The orderly transit of cells through the cell cycle
requires a delicate balance between positive and negative
regulatory factors. Any alteration in this balance can
result in abnormal cell proliferation, which may contribute
to cancer. Jab1 was initially described as a coactivator of
AP1 transcription factor and is a subunit of a large protein
complex (called the COP9 signalosome). Recent study
found that an increasing level of Jab1 causes an increasing
breakdown of p27Kip1 and indicated that Jab1 controls
the activity of p27Kip1 by facilitating its degradation. This
finding suggested that Jab1 can act as a negative regulator
of important cell cycle control proteins by targeting them
for degradation.7
The study of Claret et al. by immunofluorescence
analysis indicated that Jab1 is a nuclear protein.4 Through
selective interaction with the Jun proteins, Jab1 can
increase the specificity of target-gene activation by this
large family of related transcription factors. However, to
date, the detailed biological functions of Jab1 in
mammalian cells have not been identified.
In the present study, an antisense strategy to
investigate the effect of Jab1 on growth of head and neck
cancer cells that were overexpressing this gene was
employed. Transfection of an antisense oligonucleotide
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Figure 1: Percentages of apoptosis cells in oligonucleotide-treated Sp-C1 cells
Figure 2:  The activity of caspase-3 and -9 in Sp-C1 cell. Caspases pro-
teolytic activity was assessed using a colorimetric assay.
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(AS) into cultured Sp-C1 cells induced early and late
apoptosis (Fig.1), followed by increasing proteolytic
activity of caspase-3 (2.4 fold) and -9 (1.9 fold) (Fig. 2).
These circumstances, together with observations of cell
death in the Jab1-antisense-treated cells, prompted us to
investigate possible involvement of apoptotic mechanism
in the inhibition of cell growth following antisense
treatment. An increase in early and late apoptosis
percentation and activation of caspase-3 and –9 in AS-
treated cells strongly suggested that apoptosis had
occurred in those cultures. 
Several investigators had already detected a
relationship between Jab1 and apoptosis in their
experiments. Jab1 -/- embryonic cells, which lacked other
CSN components, expressed higher levels of p27, p53
and cyclin E, resulting in impaired proliferation and
accelerated apoptosis.31 Mutant Jab1 down-regulates the
UPR signaling pathway through tight binding with IRE1α
These result suggested that Jab1 may act as a key
molecule in selecting the UPR or cell death by association
and dissociation with IRE1α.32 However, the actual role of
Jab1 in apoptosis remains unclear. In our study found that
down regulation of Jab1 led to apoptosis. This result may
be compatible with observation that overexpression of
p27Kip1 was able to induce apoptosis in several cancer
cell lines, because expression of Jab1 is inversely
correlated with that of p27Kip1 in oral squamous cell
carcinomas.33,34
Since components of apoptotic programs represent
promising targets for anticancer therapy, down-regulation
of Jab1 by the antisense approach could be a useful
apoptosis-modulating strategy for treatment of head and
neck cancers. Further studies are needed to clarify the
apoptotic mechanism revealed here, and to determine
whether Jab1 down-regulation also induces apoptosis in
cells derived from tumors of other types.
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